Gordon J. Freeman
91Patents
26h-index
99Co-inventors
91Inventor score
Filing activity: Jan 8, 1976 → Sep 22, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5858358A | Methods for selectively stimulating proliferation of T cells | Chemistry; Metallurgy | 299 | Expired |
| US6808710B1 | Downmodulating an immune response with multivalent antibodies to PD-1 | Physics | 278 | Expired |
| US8552154B2 | Anti-PD-L1 antibodies and uses therefor | Emerging Cross-Sectional Technologies | 189 | Active |
| US7101550B2 | PD-1, a receptor for B7-4, and uses therefor | Physics | 151 | Expired |
| US7635757B2 | B7-4 Antibodies and uses therefor | Chemistry; Metallurgy | 142 | Active |
| US7105328B2 | Methods for screening for compounds that modulate pd-1 signaling | Physics | 110 | Expired |
| US6936704B1 | Nucleic acids encoding costimulatory molecule B7-4 | Chemistry; Metallurgy | 103 | Expired |
| US7709214B2 | Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1 | Physics | 84 | Active |
| US7038013B2 | B7-4 polypeptides and uses therefor | Chemistry; Metallurgy | 77 | Expired |
| US7722868B2 | Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof | Physics | 69 | Active |
| US9683048B2 | Antibody molecules to PD-1 and uses thereof | Emerging Cross-Sectional Technologies | 66 | Active |
| US7638492B2 | Methods of upmodulating an immune response with non-activating forms of B7-4 | Physics | 64 | Active |
| US6719972B1 | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies | Chemistry; Metallurgy | 62 | Expired |
| US9102727B2 | Human anti-PD-1 antibodies and uses therefor | Emerging Cross-Sectional Technologies | 61 | Active |
| US5942607A | B7-2: a CTLA4/CD28 ligand | Chemistry; Metallurgy | 57 | Expired |
| US7432059B2 | Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signal | Physics | 56 | Expired |
| US5861310A | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor | Chemistry; Metallurgy | 56 | Expired |
| US8652465B2 | Methods and compositions for the treatment of persistent infections | Emerging Cross-Sectional Technologies | 51 | Active |
| US9605070B2 | Antibody molecules to TIM-3 and uses thereof | Emerging Cross-Sectional Technologies | 50 | Active |
| US7470428B2 | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule | Chemistry; Metallurgy | 40 | Expired |
| US6130316A | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore | Chemistry; Metallurgy | 36 | Expired |
| US5858776A | Tumor cells with increased immunogenicity and uses therefor | Human Necessities | 33 | Expired |
| US8101176B2 | Compositions and methods related to TIM-3, a TH1-specific cell surface molecule | Chemistry; Metallurgy | 31 | Active |
| US7700301B2 | Methods for screening for compounds that modulate PD-1 signaling | Physics | 30 | Active |
| US8709412B2 | Modulation of TIM receptor activity in combination with cytoreductive therapy | Chemistry; Metallurgy | 29 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.